NCT02743208

Brief Summary

In recent years, short femoral stems have been introduced. Short stems are designed based on traditional stems with good clinical results. The assumed benefit of short stems is that they are easier to use in mini-invasive surgery, and that preservation of proximal periprosthetic bone stock is better. Preservation of periprosthetic bone in the proximal femur is thought to secure long time anchoring of the implant, and reduce the risk of loosening. In addition, a good proximal bone stock makes later revision surgery less technically demanding. However, the short stem design could compromise the stability of the prosthesis, and there has been reported diverging results regarding correct positioning of short stems. This may be due to the lack of inherent aiming provided by the tip of the traditional long stems. We want to clinically evaluate the stability and bone remodelling pattern of a new short femoral stem based on a standard stem with excellent long time results. In addition we will compare the two different stems regarding positioning, when using a newly developed guiding broach for the short stem, and the standard broach for the long stem. Finally, patient reported clinical outcome scores will be evaluated with respect to implant and biomechanical reconstruction. The aim of this study is to evaluate whether this specific short femoral stem is stable, safe to use, and if it provides the expected beneficial effects on bone remodelling.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Sep 2019

Typical duration for not_applicable

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 31, 2016

Completed
19 days until next milestone

First Posted

Study publicly available on registry

April 19, 2016

Completed
3.4 years until next milestone

Study Start

First participant enrolled

September 1, 2019

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2021

Completed
Last Updated

December 12, 2019

Status Verified

December 1, 2019

Enrollment Period

2 years

First QC Date

March 31, 2016

Last Update Submit

December 9, 2019

Conditions

Keywords

Arthroplasty, Replacement, HipSurgical Procedures, OperativeHip Prosthesis

Outcome Measures

Primary Outcomes (1)

  • Change in periprosthetic bone mineral density (BMD)

    Postoperative change in BMD following bone remodelling measured by dual-energy x-ray absorptiometry (DXA)

    2 years

Secondary Outcomes (5)

  • Migration of femoral stem

    2 years

  • Biomechanical reconstruction of hip anatomy

    2 years

  • Hip disability osteoarthritis outcome score (HOOS)

    2 years

  • Harris hip score

    2 years

  • Health-related quality of life (EQ-5D).

    2 years

Study Arms (2)

Furlong Evolution femoral stem

EXPERIMENTAL

Short stem hip arthroplasty (SHA) using a Furlong Evolution femoral stem, and a Furlong H-A.C. Cortical Scree Fit (CSF) plus acetabular cup system.

Device: Short stem hip arthroplasty (SHA)

Furlong H-A.C. femoral stem

ACTIVE COMPARATOR

Total hip arthroplasty (THA) using a Furlong H-A.C. femoral stem, and a Furlong H-A.C. CSF plus acetabular cup system.

Device: Total hip arthroplasty (THA)

Interventions

Furlong Evolution femoral stem

Furlong Evolution femoral stem

Furlong H-A.C. femoral stem

Furlong H-A.C. femoral stem

Eligibility Criteria

Age30 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • receiving primary total hip arthroplasty due to osteoarthritis, posttraumatic arthritis, avascular necrosis, or developmental hip dysplasia (Crowe grade 1)

You may not qualify if:

  • osteoporosis
  • pregnancy
  • musculoskeletal problems compromising rehabilitation
  • corticosteroid treatment
  • dementia
  • developmental dysplasia (Crowe grade II-IV)
  • osteosynthesis in place
  • revision surgery
  • joint infection
  • malignancy of the femur/pelvis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Osteoarthritis, Hip

Interventions

Arthroplasty, Replacement, Hip

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Intervention Hierarchy (Ancestors)

Arthroplasty, ReplacementArthroplastyOrthopedic ProceduresSurgical Procedures, OperativePlastic Surgery ProceduresProsthesis Implantation

Study Officials

  • Olav Foss, md phd

    St. Olavs Hospital

    STUDY DIRECTOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 31, 2016

First Posted

April 19, 2016

Study Start

September 1, 2019

Primary Completion

September 1, 2021

Study Completion

September 1, 2021

Last Updated

December 12, 2019

Record last verified: 2019-12

Data Sharing

IPD Sharing
Will not share